Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
23 Luglio 2024 - 1:00PM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced presentations
related to the Company’s TREM2 and progranulin programs at the
upcoming Alzheimer's Association International Conference® 2024
(AAIC®) being held online and in Philadelphia, Pennsylvania from
July 28 – August 1, 2024.
Poster presentations will be available for on-demand viewing
beginning on July 28 at 8:00 a.m. ET.
AL002 Presentations TREM2 Program
(AL002) is Being Developed in Collaboration with
AbbVie
Poster Title: Baseline characteristics for
INVOKE-2: a phase 2 randomized, double-blind, placebo-controlled
study evaluating AL002 in early Alzheimer’s disease
(#95594)Presenting Author: Arthur J. Mayorga,
Ph.D., Vice President, Clinical Development Neurology, Alector
Session Date and Time: Sunday, July 28, 2024 from
8:00 a.m. – 4:15 p.m. ET
Poster Title: Use of a blood-based amyloid test
for screening in INVOKE-2: a phase 2 randomized, double-blind,
placebo-controlled study evaluating AL002 in early Alzheimer’s
disease (#95646)Presenting Author: Brady Burgess,
Ph.D., Staff Scientist, Alector Session Date and
Time: Monday, July 29, 2024 from 8:00 a.m. – 4:15 p.m.
ET
Progranulin PresentationsProgranulin
Programs (latozinemab (AL001) and AL101/GSK4527226) are Being
Developed in Collaboration with GSK
Poster Title: Using plasma biomarkers to
distinguish TDP43 associated pathologies (#89291)Presenting
Author: Gopi Ganji, Ph.D., Scientific Leader,
GSKSession Date and Time: Monday, July 29, 2024
from 8:00 a.m. – 4:15 p.m. ET
Poster Title: PROGRESS-AD: a phase 2 study to
evaluate efficacy and safety of GSK4527226 (AL101), an
anti-sortilin monoclonal antibody, in patients with early
Alzheimer's disease (#90247)Presenting Author:
Christine Bailey, Ph.D., Clinical Development Director, GSK
Session Date and Time: Sunday, July 28, 2024 from
8:00 a.m. – 4:15 p.m. ET
Poster Topic: Genetics, progranulin, and
Alzheimer’s disease (#89497)Presenting Author:
Chun-Fand Xu, Ph.D., Senior Director, Human Genetics Senior
Director, GSKSession Date and Time: Sunday, July
28, 2024 from 8:00 a.m. – 4:15 p.m. ET
About AlectorAlector is a clinical-stage
biotechnology company pioneering immuno-neurology, a novel
therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a root
cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and seek to treat
indications, including Alzheimer’s disease and genetically defined
frontotemporal dementia patient populations. Alector is
headquartered in South San Francisco, California. For additional
information, please visit www.alector.com.
Alector Contacts:
AlectorKatie Hogan202-549-0557katie.hogan@alector.com
1AB (media)Dan Budwick973-271-6085 dan@1abmedia.com
Argot Partners (investors)Laura
Perry212.600.1902alector@argotpartners.com
Grafico Azioni Alector (NASDAQ:ALEC)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Alector (NASDAQ:ALEC)
Storico
Da Dic 2023 a Dic 2024